Literature DB >> 8772694

Alpha 1-adrenergic receptor coupling with Gh in the failing human heart.

K C Hwang1, C D Gray, W E Sweet, C S Moravec, M J Im.   

Abstract

BACKGROUND: We recently demonstrated that Gh, which transfers the signal from the alpha 1-adrenergic receptor to the 69-kD phospholipase C, is the previously identified tissue-type transglutaminase (TGase II). The alpha 1-adrenergic receptor mediates actions of the sympathetic nervous system, including cardiac, arteriolar, and smooth muscle contractions. In human cardiac tissue, the expression of the alpha 1-adrenergic receptor is increased under pathophysiological conditions, but changes in the physiological response are small. Therefore, it has been suggested that the other components involved in the alpha 1-adrenergic receptor-mediated signaling pathway are probably altered. METHODS AND
RESULTS: Immunological and biochemical studies with nonfailling and failing human heart tissues revealed that the GTP-binding and TGase activities of human heart TGase II (hhG alpha n) are downregulated in both ischemic and dilated cardiomyopathic human heart. In ischemic cardiomyopathy, the alpha 1-adrenergic receptor number increased twofold (27.0 fmol/mg) compared with the nonfailing (12.8 fmol/mg) and the dilated cardiomyopathic (15.6 fmol/mg) heart tissues, but the coupling of hhG alpha h with the alpha 1-adrenergic receptor did not increase. The intrinsic activity of hhG alpha h, was greatly decreased in membrane fractions, whereas the cytosolic TGase activity was not changed. In the dilated cardiomyopathic human heart, these intrinsic enzyme activities of hhG alpha h were also downregulated in the membrane fraction, whereas the amount of hhG alpha h protein was greatly increased (2.8-fold) compared with the nonfailing heart.
CONCLUSIONS: The results of the present study clearly demonstrate that the alpha 1-adrenergic receptor in human heart couples with Gh (TGase II) and indicate that downregulation of hhG alpha h activity is associated with human cardiac failure but that the mechanism differs between ischemic and dilated cardiomyopathies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772694     DOI: 10.1161/01.cir.94.4.718

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Protein kinetic signatures of the remodeling heart following isoproterenol stimulation.

Authors:  Maggie P Y Lam; Ding Wang; Edward Lau; David A Liem; Allen K Kim; Dominic C M Ng; Xiangbo Liang; Brian J Bleakley; Chenguang Liu; Jason D Tabaraki; Martin Cadeiras; Yibin Wang; Mario C Deng; Peipei Ping
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

3.  Delta-opioid augments cardiac contraction through β-adrenergic and CGRP-receptor co-signaling.

Authors:  Vince T Nguyen; Yewen Wu; Ashley N Guillory; Bradley K McConnell; Kenichi Fujise; Ming-He Huang
Journal:  Peptides       Date:  2011-11-15       Impact factor: 3.750

4.  Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2.

Authors:  C Parker; Q Li; D Fedida
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Tissue-specific responses to loss of transglutaminase 2.

Authors:  Stephanie Deasey; Shobana Shanmugasundaram; Maria Nurminskaya
Journal:  Amino Acids       Date:  2011-12-23       Impact factor: 3.520

Review 6.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.

Authors:  Brian C Jensen; Timothy D O'Connell; Paul C Simpson
Journal:  J Mol Cell Cardiol       Date:  2010-11-28       Impact factor: 5.000

Review 7.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

Review 8.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

9.  Quantification of [11C]GB67 binding to cardiac alpha1-adrenoceptors with positron emission tomography: validation in pigs.

Authors:  So-Jin Park-Holohan; Marie-Claude Asselin; David R Turton; Sharron L Williams; Susan P Hume; Paolo G Camici; Ornella E Rimoldi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-15       Impact factor: 9.236

Review 10.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.